

This material is an English translation of the press release announced on March 1, 2019 in Japanese, and the Japanese release is given priority about the content and the interpretation.

---

March 1, 2019

## Notification of a Subsidiary's Share Transfer

Hisamitsu Pharmaceutical Co., Ltd. (Headquarters: Tosu City, Saga Prefecture, Chairman and Chief Executive Officer (CEO): Hirotaka Nakatomi, hereinafter "Hisamitsu Pharmaceutical") concluded the share purchase agreement with CLEA Japan, Inc. (Headquarters: Meguro, Tokyo Prefecture, Representative Director: Shigenobu Kimoto, hereinafter "CLEA Japan") and all of the shares of Hisamitsu Pharmaceutical's wholly-owned subsidiary, KYUDO. CO., LTD. (Headquarters: Tosu City, Saga Prefecture, Representative Director: Mitsutoshi Tsuruta) were transferred to CLEA Japan on February 28, 2019.

Hisamitsu Pharmaceutical will continue to make efforts to improve peoples' QOL around the world and sustainable corporate value by focusing our managerial resources on pharmaceutical business and this decision is consistent with above purposes.

The impact on earnings for the fiscal year ending February 28, 2019 is negligible.

### KYUDO. CO., LTD.

- |                          |   |
|--------------------------|---|
| (1) Name                 | KYUDO. CO., LTD.                                      |
| (2) Address              | 883-1, Souraku, Tateishi, Tosu city, Saga prefecture  |
| (3) Business description | Production, breeding and sale of experimental animals |
| (4) Capital              | 10 million yen  |